ASTRAZENECA PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11,988 GBX | -0.32% |
|
+9.90% | +13.49% |
| Apr. 25 | Health Care Drops Amid Mixed Earnings -- Health Care Roundup | DJ |
| Apr. 25 | Sector Update: Health Care Stocks Decline Late Afternoon | MT |
Financials (USD)
| Sales 2024 * | 50.96B | Sales 2025 * | 54.51B | Capitalization | 233B |
|---|---|---|---|---|---|
| Net income 2024 * | 8.59B | Net income 2025 * | 10.22B | EV / Sales 2024 * | 4.96 x |
| Net Debt 2024 * | 19.72B | Net Debt 2025 * | 13.33B | EV / Sales 2025 * | 4.52 x |
| P/E ratio 2024 * |
27.7
x | P/E ratio 2025 * |
23.2
x | Employees | 89,900 |
| Yield 2024 * |
2.05% | Yield 2025 * |
2.17% | Free-Float | 96.5% |
More Fundamentals
* Assessed data
More news
Latest transcript on AstraZeneca PLC
More recommendations
More press releases
More news
| 1 day | +5.94% | ||
| 1 week | +10.19% | ||
| Current month | +12.62% | ||
| 1 month | +15.70% | ||
| 3 months | +15.10% | ||
| 6 months | +14.03% | ||
| Current year | +13.45% |
1 week
11 004.00
12 096.00
1 month
10 417.6112 096.00
Current year
9 461.0012 096.00
1 year
9 461.0012 186.00
3 years
7 392.0012 392.00
5 years
5 626.0012 392.00
10 years
3 680.0012 392.00
| Managers | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 63 | 12-09-30 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 21-07-31 |
Cindy Hoots
CTO | Chief Tech/Sci/R&D Officer | 56 | 19-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sherilyn McCoy
BRD | Director/Board Member | 65 | 17-09-30 |
Ahmed Hamdy
PRN | Corporate Officer/Principal | 59 | 13-01-31 |
Philip Broadley
BRD | Director/Board Member | 63 | 17-04-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 9.20% | 11 M€ | +0.83% | - | |
| 5.39% | 192 M€ | +11.66% | ||
| 5.17% | 18 M€ | +3.79% | - | |
| 4.89% | 776 M€ | +7.70% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 12,022 | -0.03% | 156 372 |
| 24-04-25 | 12,026 | +5.94% | 4,952,967 |
| 24-04-24 | 11,352 | +0.75% | 3,596,131 |
| 24-04-23 | 11,268 | +0.16% | 3,561,073 |
| 24-04-22 | 11,250 | +2.78% | 3,448,159 |
Delayed Quote London S.E., April 25, 2024 at 11:35 am EDT
More quotes
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
2024-04-28
- Roadshow - Day 1
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
150.3
USD
Average target price
161.4
USD
Spread / Average Target
+7.44%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +13.45% | 233B | |
| +24.17% | 556B | |
| -6.33% | 354B | |
| +19.90% | 331B | |
| +7.95% | 296B | |
| +6.04% | 201B | |
| -10.51% | 193B | |
| -12.26% | 143B | |
| -6.47% | 144B | |
| +2.07% | 123B |
- Stock Market
- Equities
- AZN Stock
